by Mark Chiang

马克·蒋

Share To

分享到

Vividion Therapeutics has obtained global rights to advance and market VVD-214, a covalent inhibitor targeting Werner helicase (WRN). The agreement grants the Bayer subsidiary exclusive control over the development and commercialization of the compound.

Vividion Therapeutics已获得推进和销售靶向Werner解旋酶（WRN）的共价抑制剂VVD-214的全球权利。该协议授予拜耳子公司对这种化合物开发和商业化的独家控制权。

Werner helicase is associated with DNA repair processes, and its inhibition has been studied for potential therapeutic applications. VVD-214 specifically targets WRN through a covalent mechanism, which may offer precision in addressing diseases linked to this enzyme. This acquisition positions Vividion to further explore the compound’s capabilities and bring it to market if successful..

维尔纳解旋酶与DNA修复过程相关，其抑制作用已被研究用于潜在的治疗应用。VVD-214通过共价机制特异性靶向WRN，这可能为解决与此酶相关的疾病提供精准性。此次收购使Vividion能够进一步探索该化合物的能力，并在成功的情况下将其推向市场。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: June 5, 2025

日期：2025年6月5日

Related posts:

相关文章:

Drug Patent Watch: Personalized Medicine and Patient Engagement Platforms Emerging as Key Strategies in Pharmaceutical Marketing

药物专利观察：个性化医疗和患者参与平台成为制药营销的关键策略

DrugPatentWatch: Strong Pharmaceutical Patents Key to Commercial Success, Influenced by Scientific Understanding and Competitive Landscape.

DrugPatentWatch：强大的制药专利是商业成功的关键，受科学理解和竞争格局的影响。

CDMO Outsourcing: API Costs Vary Widely, Ranging from $5 to $50 Per Gram

CDMO外包：API成本差异很大，每克从5美元到50美元不等。

Drug Patent Watch Highlights the Importance of Well-Drafted Patent Applications for Biologic Drugs

药物专利观察强调了为生物药物精心起草专利申请的重要性

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·江

Related Post

相关文章

News Flash

新闻快讯

Robert Kennedy Advocates for Patient Access to Experimental Stem Cell Therapies Despite Safety Concerns

罗伯特·肯尼迪倡导患者获取实验性干细胞疗法，尽管存在安全顾虑

2025-06-05

2025年6月5日